Management of the medically fit/intermediate fitness patient with high risk/very high risk MDS who is a candidate for allogeneic HCT

This algorithm presents our approach to management of high/very high risk MDS (ie, IPSS-R >4) in a patient who is a candidate for intensive therapy (eg, allogeneic HCT or intensive remission induction therapy). Selection of therapy is influenced by clinician/institution and patient preferences. This algorithm should be used in conjunction with related UpToDate topics.

MDS: myelodysplastic syndromes; HCT: hematopoietic cell transplantation; HMA: hypomethylating agent; IDH: isocitrate dehydrogenase; CR: complete remission; BM: bone marrow; IPSS-R: international prognostic scoring system, revised.
* Definition of adverse genetic features may vary by institution.
¶ If HMA is selected and TP53 mutation is present, some experts prefer decitabine rather than azacitidine.

Graphic 119697 Version 1.0

خرید پکیج

Management of the medically fit/intermediate fitness patient with high risk/very high risk MDS who is a candidate for allogeneic HCT